EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

Ron Handels, William L Herring, Farzam Kamgar, Sandar Aye, Ashley Tate, Colin Green, Anders Gustavsson, Anders Wimo, Bengt Winblad, Anders Sköldunger, Lars Lau Raket, Chelsea Bedrejo Stellick und 11 weitere

Value in Health · 2025

DOI: 10.1016/j.jval.2024.09.006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Value in Health, 2025. Verfasst von Ron Handels und 22 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Centre Limburg, Faculty of Health Medicine and Life Sciences, School for Mental Health and Neuroscience, Department of Psychiatry and Neuro…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cost-Benefit Analysis, Cognitive Dysfunction, Decision Support Techniques. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Decision-analytic models assessing the value of emerging Alzheimer's disease (AD) treatments are challenged by limited evidence on short-term trial outcomes and uncertainty in extrapolating long-term patient-relevant outcomes. To improve understanding and foster transparency and credibility in modeling methods, we cross-compared AD decision models in a hypothetical context of disease-modifying treatment for mild cognitive impairment (MCI) due to AD. METHODS: A benchmark scenario (US setting) was used with target population MCI due to AD and a set of synthetically generated hypothetical trial efficacy estimates. Treatment costs were excluded. Model predictions (10-year horizon) were assessed and discussed during a 2-day workshop. RESULTS: Nine modeling groups provided model predictions. Implementation of treatment effectiveness varied across models based on trial efficacy outcome selection (clinical dementia rating - sum of boxes, clinical dementia rating - global, mini-mental state examination, functional activities questionnaire) and analysis method (observed severity transitions, change from baseline, progression hazard ratio, or calibration to these). Predicted mean time in MCI ranged from 2.6 to 5.2 years for control strategy and from 0.1 to 1.0 years for difference between intervention and control strategies. Predicted quality-adjusted life-year gains ranged from 0.0 to 0.6 and incremental costs (excluding treatment costs) from -US$66 897 to US$11 896. CONCLUSIONS: Trial data can be implemented in different ways across health-economic models leading to large variation in model predictions. We recommend (1) addressing the choice of outcome measure and treatment effectiveness assumptions in sensitivity analysis, (2) a standardized reporting table for model predictions, and (3) exploring the use of registries for future AD treatments measuring long-term disease progression to reduce uncertainty of extrapolating short-term trial results by health-economic models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCost-Benefit AnalysisCognitive DysfunctionDecision Support TechniquesHumansQuality-Adjusted Life YearsModels, EconomicDisease ProgressionAged

Stichwörter der Autor:innen

Alzheimer’s diseasecross-validationdecision-analytic modelinghealth-economic evaluation

Autor:innen und Institutionen

  • Alzheimer Centre Limburg, Faculty of Health Medicine and Life Sciences, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; Divisi…
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden; Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden; Biogen Idec Ltd, Maidenhead, England, UK.
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden; Quantify Research, Stockholm, Sweden.

Förderung

  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Handels, R., Herring, W. L., Kamgar, F., Aye, S., Tate, A., Green, C., Gustavsson, A., Wimo, A., Winblad, B., Sköldunger, A., Raket, L. L., Stellick, C. B., Spackman, E., Hlávka, J., Wei, Y., Mar, J., Soto-Gordoa, M., de Kok, I., Brück, C., …, & Jönsson, L. (2025). IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease. Value in Health. https://doi.org/10.1016/j.jval.2024.09.006

Vancouver

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, et al. IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease. Value in Health. 2025. doi:10.1016/j.jval.2024.09.006

BibTeX
@article{Handels2025,
  author = {Handels, Ron and Herring, William L and Kamgar, Farzam and Aye, Sandar and Tate, Ashley and Green, Colin and Gustavsson, Anders and Wimo, Anders and Winblad, Bengt and Sköldunger, Anders and Raket, Lars Lau and Stellick, Chelsea Bedrejo and Spackman, Eldon and Hlávka, Jakub and Wei, Yifan and Mar, Javier and Soto-Gordoa, Myriam and de Kok, Inge and Brück, Chiara and Anderson, Robert and Pemberton-Ross, Peter and Urbich, Michael and Jönsson, Linus},
  title = {IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease},
  journal = {Value in Health},
  year = {2025},
  doi = {10.1016/j.jval.2024.09.006}
}
Kostenlos starten →